Compare Pfizer Inc (PFE) vs RLX Technology Inc (RLX) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

RLX trades at $2.06, up 0.49% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 net income of $921.87M and a net margin of 22.47%. Recent news highlights the company's cash-rich, debt-free position and its positioning in the growing global vaping market.

The outlook is mixed; strong fundamentals and market growth potential are offset by consecutive earnings misses and a single analyst's hold rating. Key risks include regulatory scrutiny in the vaping industry and execution challenges in international expansion. The stock presents a speculative opportunity for investors comfortable with sector-specific regulatory risks.